EN DE
Watch Gushengtang Holdings Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Gushengtang Holdings Ltd (2273) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Gushengtang Holdings Ltd stock HK$62.36, price HK$29.02, upside +114.9%, quality 70 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG4212K1040

GH Gushengtang Holdings Ltd logo Broad data Nov 11, 2026

Gushengtang Holdings Ltd

2273 · HK

Cheap (53% below fair value) and solid company, but price moving sideways: meets 2 of 3 rules.

Get notified free when this changes
Fair value HK$62.36 · Strongly undervalued 
Quality 70/100 
Healthy Growth (revenue 5y +28.6 %/yr in CNY) 
Solidly profitable · 12.4% net margin (TTM) 
Low debt 
Generates free cash flow 
5.6% dividend yield · Well covered
Ranks above peers (12/14) 
Broad data 
Even on cautious assumptions the value is 40% above the price (HK$40.54). 
Price moving sideways (no uptrend) 
Moderate moat 60/100 · thin data
Watch Gushengtang Holdings Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$56.41 HK$19.51 Fair Value HK$62.36 Dec 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

59‑month range HK$19.51 – HK$56.41 · fair‑value band HK$40.54 – HK$81.06 · the HK$29.02 price screens below the HK$62.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Gushengtang Holdings in your weekly email

Every Wednesday you see whether Gushengtang Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Gushengtang Holdings Limited, an investment holding company, provides healthcare services in the People's Republic of China. The company offers consultation, traditional massage, moxibustion, acupuncture, and other therapies.

Show moreShow less

It is also involved in the wholesale of pharmaceutical products; and provision of investment management and supply chain management services. The company was formerly known as Gushengtang (Cayman) Ltd. and changed its name to Gushengtang Holdings Limited in September 2021.

The company was founded in 2010 and is headquartered in Guangzhou, the People's Republic of China.

Stock analysis

Gushengtang Holdings Ltd (2273) currently trades at HK$29.02, while our model-based Fair Value estimate is HK$62.36, implying the stock looks roughly 53% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of HK$72.42 per share, and 21 of the 26 models we run sit above the HK$29.02 price.

Bear case: the Economic Profit group reads lowest at HK$24.79, and 5 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: HK$40.54 (bear) to HK$81.06 (bull), the price of HK$29.02 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Gushengtang Holdings Ltd reported revenue of 3.2B CNY in FY2025 versus 1.4B CNY in FY2021, a compound +24.0%/yr. Reported net income was 353M CNY in FY2025.

Key figures

Market cap HK$7.0B (≈ $896M) Small · P/E ratio 16.0 · P/S ratio 1.73 · Dividend yield 5.6% · Net margin 10.9% · Return on equity 19.6% · Return on assets (EBIT) 7.0% (5-year average) · Operating margin 11.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 17% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at 115%, 2273 screens cheaper than that median.

Fair Value models

Bear HK$40.54 Fair Value HK$62.36 Bull HK$81.06
Price HK$29.02 · Upside +114.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$44.01 HK$63.28 HK$121.48 77
Growth DCF HK$41.50 HK$67.61 HK$116.37 76
Residual Income HK$11.87 HK$15.05 HK$21.77 75
All 26 models by family
DCF Models
FCF DCF HK$44.01 HK$63.28 HK$121.48 77
Owner Earnings HK$36.86 HK$73.39 HK$142.79 72
5Y Revenue Exit HK$33.23 HK$53.19 HK$94.14 70
5Y EBITDA Exit HK$42.15 HK$71.45 HK$128.00 72
5Y P/E Exit HK$38.84 HK$77.56 HK$129.21 68
10Y Revenue Exit HK$35.85 HK$67.91 HK$89.85 66
10Y EBITDA Exit HK$42.76 HK$85.37 HK$162.74 65
10Y P/E Exit HK$40.52 HK$78.89 HK$144.24 61
Earnings-Based
Graham-Dodd HK$13.33 HK$92.95 HK$130.44 63
Lynch FV HK$35.41 HK$50.59 HK$65.76 61
PEG = 1.0 HK$35.41 HK$50.59 HK$65.76 57
EPV HK$21.42 HK$23.89 HK$25.98 74
Dividend Discount
Gordon GGM HK$15.80 HK$29.27 HK$41.29 67
DDM Multi-Stage HK$15.80 HK$26.34 HK$31.17 67
Multiples
P/E Multiple HK$32.34 HK$43.12 HK$53.90 63
P/S Multiple HK$24.99 HK$33.32 HK$41.65 58
P/B Multiple HK$15.20 HK$20.27 HK$25.34 55
EV/EBIT HK$32.46 HK$43.04 HK$53.62 66
EV/EBITDA HK$37.81 HK$50.18 HK$62.54 67
EV/Revenue HK$23.37 HK$33.08 HK$42.79 54
Asset-Based
NCAV (Graham) HK$0.1200 HK$0.1900 HK$0.2300 55
Growth DCF
Growth DCF HK$41.50 HK$67.61 HK$116.37 76
Rev-Margin DCF HK$33.23 HK$60.27 HK$106.50 70
Economic Profit
Residual Income HK$11.87 HK$15.05 HK$21.77 75
ROIC Compounder HK$25.68 HK$34.53 HK$45.77 72
Growth Earnings
Growth-Adj P/E HK$43.63 HK$62.33 HK$81.03 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 70/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 55
How much profit the company makes from its sales and capital
Quality Growth 55
Are margins and returns getting better?
Cashflow 72
Do the profits arrive as real cash?
Financial strength 90
Debt, balance sheet and risk of trouble
Investment 59
Does it invest with discipline instead of growing at any price?
Low Volatility 75
How calm the share price moves, does not count
Price momentum 45
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 50
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.9%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+23.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.6%
Dividend (yield on the price)5.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 14%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.2%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −1.8% a year for the price and +11.7% for the forecasts.
Forecast 2026 (sales)+14.5%
Forecast 2027 (sales)+16.1%
Projected 2028 (sales)+14.3%
Projected 2029 (sales)+12.5%
Projected 2030 (sales)+10.8%

Watch 2273, get fair value alerts →

Compare Gushengtang Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 70 · Top 25%
Fair Value upside +114.9% · Top 25%
Profitability
Return on equity (12 months) 19.6% · Top 25%
Return on assets 8.8% · Top 25%
Net margin (12 months) 12.4% · Top 25%
Operating margin (12 months) 11.5% · Above median
Growth and dividend
Revenue growth (quarter YoY) 10.6% · Above median
Dividend yield (12 months) 5.6% · Top 25%
Balance sheet
Debt / equity 0.09× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 16.0× · Cheaper than median
P/B 2.75× · Pricier than median
P/S (12 months) 1.75× · Pricier than median
Price / free cash flow (fiscal year) 12.4× · Cheaper than median
EV/EBITDA 10.5× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 34
FUTURE (revenue growth)53 · sector 31
PAST (return on equity)79 · sector 31
HEALTH (low debt)96 · sector 90
DIVIDEND (yield)100 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $45.73 +108% vs 2273
DaVita Inc DVA $174.56 $218.90 +25% vs 2273
Aier Eye Hospital Group 300015 ¥8.84 ¥10.88 +23% vs 2273
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs 2273
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs 2273
The Ensign Group ENSG $188.41 $140.09 −26% vs 2273
Encompass Health Corporation EHC $140.99 $94.81 −33% vs 2273
Fresenius SE FRE €53.62 €34.77 −35% vs 2273
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,526 ₹5,234 −39% vs 2273
Dr. Sulaiman Al Habib Medical Services Group 4013 212.10 SAR 109.45 SAR −48% vs 2273

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Gushengtang Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Gushengtang Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2273

Frequently asked questions

Is Gushengtang Holdings Ltd (2273) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of HK$62.36 versus a price of HK$29.02, about +115% upside (undervalued).
What is the fair value of 2273?
Our model-based fair value for Gushengtang Holdings Ltd is HK$62.36 (as of Nov 11, 2026), built from audited fundamentals. The current price: HK$29.02.
What is the quality score of 2273?
Gushengtang Holdings Ltd has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gushengtang Holdings Ltd (2273)?
Our model-based price target is the fair value of HK$62.36 (as of Nov 11, 2026) from 26 valuation models. Cautious scenario HK$40.54, optimistic scenario HK$81.06. It is a calculation from audited fundamentals, not an analyst target.
What is the Gushengtang Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$62.36, about +115% upside versus a price of HK$29.02 (undervalued). Cautious scenario HK$40.54, optimistic scenario HK$81.06. The calculation is refreshed regularly with new filings.
What is the revenue of Gushengtang Holdings Ltd (2273)?
Gushengtang Holdings Ltd reported trailing-twelve-month revenue of about 3.4B CNY (latest available figure, as of Nov 11, 2026).
Does Gushengtang Holdings Ltd pay a dividend?
Gushengtang Holdings Ltd currently shows a dividend yield of 5.55% relative to its recent price (as of Nov 11, 2026).
How much is the dividend of Gushengtang Holdings Ltd (2273) and when is the ex-dividend date?
Gushengtang Holdings Ltd pays a dividend of HK$1.61 per share a year, a dividend yield of 5.6%. The last ex-dividend date was Sep 30, 2026. The payout ratio is 45.1% of earnings. Free cash flow covers the dividend 3.03 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Gushengtang Holdings Ltd (2273)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at Gushengtang Holdings Ltd shrinks by 0.2 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 28.6 % per year. As of Nov 11, 2026.
What discount rate (WACC) does the fair value of 2273 use?
Our models discount Gushengtang Holdings Ltd at 10.5 %: a base by market capitalisation (small), damped by beta 0.58, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Gushengtang Holdings Ltd that is -0.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Gushengtang Holdings Ltd (2273) delivered so far?
Over the past 5 years revenue at Gushengtang Holdings Ltd grew 28.6 % a year. The price currently implies free-cash-flow growth of -0.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Gushengtang Holdings Ltd (2273) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Gushengtang Holdings Ltd (-0.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Gushengtang Holdings Ltd (2273)?
The free-cash-flow yield on the price is 8.08 %: that much free cash flow Gushengtang Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Gushengtang Holdings Ltd (2273)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gushengtang Holdings Ltd it is HK$62.36 per share (as of Nov 11, 2026), against a price of HK$29.02. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Gushengtang Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 11, 2026, 2273 trades below its calculated fair value: price HK$29.02, fair value HK$62.36, a gap of about +115% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2273?
No. The price is what the market pays today (HK$29.02); the fair value is what the company's own numbers justify (HK$62.36). For Gushengtang Holdings Ltd the two are HK$33.34 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gushengtang Holdings Ltd worth?
The market values Gushengtang Holdings Ltd at about HK$7.0B (market capitalisation, as of Nov 11, 2026). Per share that is HK$29.02; our models calculate a fair value of HK$62.36 per share.
What do the bullish and bearish scenarios say about 2273?
Our models span a range for Gushengtang Holdings Ltd: cautious scenario HK$40.54, base HK$62.36, optimistic HK$81.06 per share (as of Nov 11, 2026, price HK$29.02). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2273?
Gushengtang Holdings Ltd trades at a price-to-earnings ratio of 16.0 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$62.36 is built from several models across several years. Other multiples: P/B 2.8, P/S 1.8, EV/EBITDA 10.5.
How solid is the balance sheet of Gushengtang Holdings Ltd (2273)?
Balance-sheet figures for Gushengtang Holdings Ltd (as of Nov 11, 2026): return on equity 19.6%, debt of 0.09 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 2273 from its 52-week high?
Gushengtang Holdings Ltd trades at HK$29.02, about 9% below its 52-week high of HK$31.74 and 17% above the low of HK$24.81 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$62.36 is for.
Which stocks are comparable to Gushengtang Holdings Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gushengtang Holdings Ltd stock attractive at the current price?
The data as of Nov 11, 2026: price HK$29.02, calculated fair value HK$62.36 (+115%), Quality Score 70/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2273 calculated?
We run Gushengtang Holdings Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$62.36 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Gushengtang Holdings Ltd currently trades 53% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gushengtang Holdings Ltd (2273)?
The closing price on Nov 13, 2026 was HK$29.02. Our model-based fair value is HK$62.36, about +115% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gushengtang Holdings Ltd right now?
The price is below even our cautious bear case (HK$40.54). The market is more pessimistic than our downside scenario. Solid quality (70/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$40.54 to HK$81.06) leaves room in how you read the outcome.

Key figures of Gushengtang Holdings Ltd

How large is the market capitalisation of Gushengtang Holdings Ltd (2273)?
The market capitalisation of Gushengtang Holdings Ltd is HK$7.0B (≈ $896M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gushengtang Holdings Ltd (2273)?
The price-to-sales ratio of Gushengtang Holdings Ltd is 1.73 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Gushengtang Holdings Ltd (2273)?
The dividend yield of Gushengtang Holdings Ltd is 5.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Gushengtang Holdings Ltd (2273)?
The net margin of Gushengtang Holdings Ltd is 10.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gushengtang Holdings Ltd (2273)?
The return on equity (ROE) of Gushengtang Holdings Ltd is 19.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gushengtang Holdings Ltd (2273)?
On an EBIT basis the return on assets of Gushengtang Holdings Ltd is 7.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gushengtang Holdings Ltd (2273)?
The operating margin of Gushengtang Holdings Ltd is 11.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gushengtang Holdings Ltd (2273)?
Revenue at Gushengtang Holdings Ltd is growing 10.6% versus a year earlier (3y avg +26.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gushengtang Holdings Ltd (2273)?
Earnings per share at Gushengtang Holdings Ltd are growing 47.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Gushengtang Holdings Ltd (2273) hold?
Gushengtang Holdings Ltd holds more cash than debt, 129M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Gushengtang Holdings Ltd in the live analysis

One click puts Gushengtang Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.